- Home
- KBON vs CBIO Comparison
KBON vs CBIO Comparison
Compare KBON & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KBON | CBIO |
|---|---|---|
| Founded | 2025 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.8M | 471.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KBON | CBIO |
|---|---|---|
| Price | $10.08 | $15.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 64.8K | ★ 386.6K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.04 | $8.72 |
| 52 Week High | $10.15 | $27.41 |
Technical Indicators
Market Signals| Indicator | KBON | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 39.97 |
| Support Level | $10.05 | $14.69 |
| Resistance Level | $10.12 | $15.96 |
| Average True Range (ATR) | 0.02 | 1.42 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 50.00 | 9.01 |
Price Performance
Historical ComparisonAbout KBON Karbon Capital Partners Corp. Class A Ordinary Shares
Karbon Capital Partners Corp is a blank check company.
About CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.